Rituximab pharmacokinetics in children and adolescents withde novointermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report-Reference-Cited by-同舟云学术

Rituximab pharmacokinetics in children and adolescents withde novointermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report

Published:2013-06-27 Issue:5 Volume:162 Page:678-683
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Barth Matthew J.¹,Goldman Stanton²,Smith Lynette³,Perkins Sherrie⁴,Shiramizu Bruce⁵,Gross Thomas G.⁶,Harrison Lauren⁷,Sanger Warren⁸,Geyer Mark B.⁹,Giulino-Roth Lisa,Cairo Mitchell S.

Affiliation:

1. Division of Pediatric Hematology/Oncology; University at Buffalo; Buffalo; NY; USA

2. Division of Pediatric Hematology/Oncology; Medical City Children's Hospital; Dallas; TX; USA

3. Department of Biostatistics; University of Nebraska; College of Public Health; Omaha; NE; USA

4. Department of Pathology; University of Utah; Salt Lake City; UT; USA

5. Division of Pediatric Hematology/Oncology; University of Hawaii; Honolulu; HI; USA

6. Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation; Ohio State University; Columbus; OH; USA

7. Department of Pediatrics; New York Medical College; Valhalla; NY; USA

8. Department of Cytogenetics; University of Nebraska Medical Center; Omaha; NE; USA

9. Department of Medicine; Massachusetts General Hospital; Harvard Medical School; Boston; MA; USA

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.12434/fullpdf

Reference14 articles.

1. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura;Bennett;Blood,2006

2. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents;Cairo;Blood,2007

3. Safety, kinetics, and outcome following rituximab (R) in combination with FAB chemotherapy in children and adolescents (C+A) with stage III/IV (Group B) and BM+/CNS+ (Group C) mature B-NHL: a Children's Oncology Group report;Cairo;Journal of Clinical Oncology,2010

4. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (≥15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study;Cairo;Journal of Clinical Oncology,2012

5. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;The New England Journal of Medicine,2002

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic drug monitoring in childhood idiopathic nephrotic syndrome: a state of the art review;Pediatric Nephrology;2023-05-06

2. Patient parameters and response after administration of rituximab in pediatric mature B‐cell non‐Hodgkin lymphoma;Pediatric Blood & Cancer;2021-12-22

3. Outcomes of Burkitt lymphoma with bone marrow involvement or Burkitt leukemia in Chinese children;Pediatric Investigation;2021-06

4. A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma;Leukemia;2021-05-03

5. Younger children treated with rituximab for nephrotic syndrome are at higher risk of adverse events;Nephrology Dialysis Transplantation;2021-02-04